Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.69 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.52 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.48 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
| ▸ | CASP2 | P42575 | 1/20 | 0.45 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22923670 | 0.97 | GLP1R (0.73) | GLP1RLPAR3LPAR1TLR2NOD1 | |
| SCHEMBL27117453 | 0.95 | GLP1R (0.68) | GLP1RLPAR3LPAR1TLR2NOD1 | |
| SCHEMBL27109668 | 0.93 | GLP1R (0.68) | GLP1RLPAR3LPAR1TLR2CASP2 | |
| SCHEMBL19320390 | 0.88 | GLP1R (0.58) | GLP1RLPAR3LPAR1TLR2NOD1 | |
| SCHEMBL27109976 | 0.87 | GLP1R (0.54) | GLP1RLPAR3LPAR1TLR2CNR1 | |
| SCHEMBL15259274 | 0.86 | GLP1R (0.75) | GLP1RLPAR3LPAR1TLR2NOD1 | |
| SCHEMBL27109672 | 0.86 | GLP1R (0.54) | GLP1RLPAR3LPAR1TLR2NOD1 | |
| SCHEMBL27117910 | 0.86 | GLP1R (0.65) | GLP1RLPAR3LPAR1TLR2NOD1 | |
| SCHEMBL22055445 | 0.86 | GLP1R (0.65) | GLP1RLPAR3LPAR1TLR2NOD1 | |
| SCHEMBL27142852 | 0.86 | GLP1R (0.65) | GLP1RLPAR3LPAR1TLR2NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044549-A1 | VHH ANTIBODY CONJUGATES | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044552-A1 | VHH ANTIBODY DOTA CONJUGATES | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |